Additional Cycle of Pembrolizumab

Phase 2Monoclonal antibody

Additional Cycle of Pembrolizumab is one of 14 small molecule programs targeting Neoadjuvant Immunotherapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoadjuvant ImmunotherapyNot yet recruiting

Neoadjuvant ImmunotherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

14 competitors in Neoadjuvant Immunotherapy

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

2 2

Abraxane

Bristol-Myers Squibb

Phase 2

2 3

Eloxatin

Teva

Phase 2

1 4

Paraplatin

AAvyxa

Phase 2

4 5

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 6

Herceptin

OOrganon and Co

Phase 2

1 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 8

Alimta

SShawn Eagle

Phase 2

1 9

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 10

Capeox

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Not yet recruiting

Neoadjuvant Immunotherapy

NCT07409844

Clinical

Trials by Indication[1]

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

Not yet recruiting·IIsmail Gögenur·Phase 2·NCT07409844·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Additional Cycle of Pembrolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Additional Cycle of Pembrolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Additional Cycle of Pembrolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ismail Gögenur company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: IIsmail Gögenur

Additional Cycle of Pembrolizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Neoadjuvant Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News